Estimating minimally important differences for the PROMIS pain interference scales: results from 3 randomized clinical trials

被引:137
|
作者
Chen, Chen X. [1 ]
Kroenke, Kurt [2 ,3 ,4 ]
Stump, Timothy E. [5 ]
Kean, Jacob [6 ,7 ]
Carpenter, Janet S.
Krebs, Erin E. [8 ,9 ]
Bair, Matthew J. [2 ,3 ,4 ]
Damush, Teresa M. [2 ,3 ,4 ,10 ]
Monahan, Patrick O. [5 ]
机构
[1] Indiana Univ, Sch Nursing, Indianapolis, IN 46204 USA
[2] Indiana Univ Sch Med, Indianapolis, IN 46202 USA
[3] Regenstrief Inst Inc, Indianapolis, IN USA
[4] VA Hlth Serv Res & Dev, Ctr Hlth Informat & Commun, Indianapolis, IN USA
[5] Indiana Univ Sch Med, Dept Biostat, Indianapolis, IN 46202 USA
[6] Univ Utah, Sch Med, Dept Populat Hlth Sci, Salt Lake City, UT USA
[7] VA Salt Lake City Hlth Care Syst, Decision Enhancement & Analyt Sci Ctr, Informat, Salt Lake City, UT USA
[8] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA
[9] Minneapolis VA Ctr Chron Dis Outcomes Res, Minneapolis, MN USA
[10] Precis Monitoring Qual Improvement PRIS M QUERI, Indianapolis, IN USA
关键词
PROMIS; Pain measurement; Pain interference; Minimally important difference; Psychometrics; Patient-reported outcome measures; OUTCOMES MEASUREMENT; INTRAINDIVIDUAL CHANGES; RESPONSIVENESS;
D O I
10.1097/j.pain.0000000000001121
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Minimally important difference (MID) refers to the smallest meaningful difference that carries implications for patient care. Minimally important differences are necessary to help interpret patient-reported pain outcomes in research and clinical practice. The PROMIS pain interference scales were validated across diverse samples; however, more information about their MIDs could improve their interpretability. The purpose of this study was to estimate MIDs for 4 fixed-length PROMIS pain interference scales, including the 6-item Pain Short Form and the 4-, 6-, and 8-item pain interference scales used in the PROMIS profile instruments. Data were analyzed from 3 randomized controlled trials (N = 759). The 3 samples, respectively, consisted of patients with chronic low back pain (n = 261), chronic back pain or hip/knee osteoarthritis pain (n = 240), and a history of stroke (n = 258). For each sample, anchor-and distribution-based approaches were used to estimate MIDs. Standard error of measurement and effect sizes were used as distribution-based MID estimates. Anchor-based MID estimates were established by mapping PROMIS pain interference scores onto established anchor measures, including the Brief Pain Inventory, and retrospective and prospective global ratings of change. The distribution-and anchor-based MID estimates showed convergence. For the pain samples, MID estimates ranged from 2 to 3 T-score points. For the nonpain sample, MID estimates ranged from 3.5 to 4.5 T-score points. The MID estimates were comparable across the 4 fixed-length scales. These MIDs can be used to evaluate treatment effects in research and clinical care and to calculate estimates for powering clinical trials.
引用
收藏
页码:775 / 782
页数:8
相关论文
共 50 条
  • [41] Email recruitment for chronic pain clinical trials: results from the LAMP trial
    Ferguson, John E.
    Campbell, Emily Hagel
    Bangerter, Ann
    Cross, Lee J. S.
    Allen, Kelli D.
    Behrens, Kimberly
    Branson, Mariah
    Calvert, Collin
    Friedman, Jessica K.
    Hennessy, Sierra
    Meis, Laura A.
    Taylor, Brent C.
    Burgess, Diana J.
    [J]. TRIALS, 2024, 25 (01)
  • [42] The fragility of statistically significant results from clinical nutrition randomized controlled trials
    Pedziwiatr, Michal
    Mizera, Magdalena
    Wysocki, Michal
    Malczak, Piotr
    Stefura, Tomasz
    Gajewska, Natalia
    Torbicz, Grzegorz
    Dros, Jakub
    Kacprzyk, Artur
    Major, Piotr
    Klek, Stanislaw
    Bala, Malgorzata
    [J]. CLINICAL NUTRITION, 2020, 39 (04) : 1284 - 1291
  • [43] The Impact of Tabalumab on the Kidney in Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized Clinical Trials
    Dooley, Mary Anne
    Rovin, Brad H.
    Radhakrishnan, Jai
    Ginzler, Ellen M.
    Forrester, Tammy
    Anderson, Pamela
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [44] The impact of tabalumab on the kidney in systemic lupus erythematosus: results from two phase 3 randomized, clinical trials
    Rovin, B. H.
    Dooley, M. A.
    Radhakrishnan, J.
    Ginzler, E. M.
    Forrester, T. D.
    Anderson, P. W.
    [J]. LUPUS, 2016, 25 (14) : 1597 - 1601
  • [45] Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: Results from a randomized clinical trial
    Kawahara, Takuya
    Taira, Naruto
    Shiroiwa, Takeru
    Hagiwara, Yasuhiro
    Fukuda, Takashi
    Uemura, Yukari
    Mukai, Hirofumi
    [J]. QUALITY OF LIFE RESEARCH, 2022, 31 (06) : 1829 - 1836
  • [46] Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: Results from a randomized clinical trial
    Takuya Kawahara
    Naruto Taira
    Takeru Shiroiwa
    Yasuhiro Hagiwara
    Takashi Fukuda
    Yukari Uemura
    Hirofumi Mukai
    [J]. Quality of Life Research, 2022, 31 : 1829 - 1836
  • [47] Sex differences in acute cannabis effects revisited: Results from two randomized, controlled trials
    Arkell, Thomas R.
    Kevin, Richard C.
    Vinckenbosch, Frederick
    Lintzeris, Nicholas
    Theunissen, Eef
    Ramaekers, Johannes G.
    McGregor, Iain S.
    [J]. ADDICTION BIOLOGY, 2022, 27 (02)
  • [48] Minimal Clinically Important Differences for PROMIS Physical Function, Upper Extremity, and Pain Interference in Carpal Tunnel Release Using Region- and Condition-Specific PROM Tools
    Bernstein, David N.
    Houck, Jeff R.
    Mahmood, Bilal
    Hammert, Warren C.
    [J]. JOURNAL OF HAND SURGERY-AMERICAN VOLUME, 2019, 44 (08): : 635 - 640
  • [49] Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma - Interpretation guidance derived from two randomized EORTC trials (vol 167C, pg 65, 2022)
    Koller, Michael
    Musoro, Jammbe Z.
    Tomaszewski, Krzysztof
    Coens, Corneel
    King, Madeleine T.
    Sprangers, Mirjam A. G.
    Groenvold, Mogens
    Cocks, Kim
    Velikova, Galina
    Flechtner, Hans-Henning
    Bottomley, Andrew
    [J]. LUNG CANCER, 2022, 171 : 126 - 126
  • [50] Duloxetine in the treatment of diabetic peripheral neuropathic pain - results from three clinical trials
    Raskin, J
    Pritchett, YL
    Chappell, AS
    D'Souza, DN
    Wong, CK
    Wernicke, JF
    [J]. DIABETOLOGIA, 2005, 48 : A82 - A82